Navigation Links
Wacker Validates Scalability of Anticalin(R) Production With E.coli Secretion Technology and Will Produce Pieris First Clinical Candidate PRS-050
Date:7/17/2008

FREISING-WEIHENSTEPHAN and JENA, Germany, July 17 /PRNewswire/ -- Pieris AG, a bio-pharmaceutical company developing Anticalins(R), a novel class of targeted human protein therapeutics, and Wacker Biotech GmbH, a full-service contract manufacturer of biopharmaceuticals, announced yesterday a significant milestone in the development of Pieris' PRS-050 Anticalin(R) for clinical trials.

Pieris has developed PRS-050 as a next generation VEGF antagonist and as the first Anticalin(R) -based product in its proprietary pipeline. PRS-050 exemplifies many of the favourable characteristics of Anticalins(R): compact protein structure, high intrinsic stability, broad formulation flexibility and small molecular size improving the likelihood of effective target access. PRS-050 has already demonstrated potent inhibition of VEGF-induced enhanced vascular permeability and angiogenesis, as well as, anti-tumour activity and is expected to enter the clinic in 2009.

Wacker's proprietary E. coli secretion system is a well-established technology for the cost-efficient production of proteins. At the core of the technology is a proprietary E. coli K12-strain, developed by Wacker, to secrete recombinant proteins in native form. Production of clinically relevant proteins via direct extracellular secretion offers a far more cost effective approach to biopharmaceutical product manufacture than traditional protein refolding technologies.

Andreas Hohlbaum Ph.D., Chief Technology Officer of Pieris, stated: "Pieris has long-established expertise in small scale expression of Anticalins(R) for research use. As we progress our products to the clinic, we have established through our relationship with Wacker that an efficient production scale-up is possible. These excellent results and subsequent agreement with Wacker will expedite process development and GMP manufacture of Anticalins(R) for both proprietary and partnered products."

Thomas Maier Ph.D., Managing Director of Wacker Biotech, commented further: "The Anticalin(R) technology is one of the most exciting 'Beyond Antibody' technologies and we are very proud to support Pieris in its aims to develop this new class of therapeutic proteins. The results obtained to date underscore the power of our E. coli secretion technology and highlight Wacker Biotech's commitment to becoming a leading force as a full-service contract manufacturer of biopharmaceuticals."

More information on Pieris AG is available at http://www.pieris-ag.com

More information on Wacker Biotech GmbH is available at http://www.wacker.com/biologics

For further information, please contact:

Pieris AG

Andreas Hohlbaum PhD, Chief Technology Officer

Phone +49(0)8161-1411-400

Wacker Chemie AG

Press and Information

Nadine Baumgartl

Phone +49(0)89-6-2791-604


'/>"/>
SOURCE Pieris AG
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. U.S. Patent Office Rejects Key HIV/AIDS Drug Patents at PUBPAT Request: Government Finds Prior Art Submitted By PUBPAT Invalidates All of Gilead Sciences Claims
2. Sarasotas Roskamp Institute Highlights Positive Japanese Data that Validates its Ongoing Alzheimers Disease Research
3. Pew Commission Says Industrial Scale Farm Animal Production Poses Unacceptable Risks to Public Health, Environment
4. Increasing Dairy Milk Production with Electrolyzed Drinking Water
5. SAIC Awarded Malaria Vaccine Production Support Contract Extension by the National Institute of Allergy and Infectious Diseases
6. New Study: Pine Bark Extract Boosts Nitric Oxide (NO) Production
7. Replidynes Investigational Antibacterial Agent REP3123 Prevents Toxin Production in Clostridium difficile
8. New Data Shows Ranexa(R) Increases Glucose-Stimulated Insulin Secretion
9. Echo Therapeutics Announces Publication of Positive Clinical Data for its Symphony Transdermal Continuous Glucose Monitoring System in Journal of Diabetes Science and Technology
10. Modigene Platform Validated in Independent Phase III Trial of CTP Technology
11. Embryo Viability Studies Support Utility of Novel, Metabolomic Profiling Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2017)... 2017 Therapix Biosciences Ltd. (Nasdaq: TRPX), ... the development of cannabinoid-based drugs, today announced that ... at three upcoming scientific and investor conferences in ... Invitational: ...                     Wednesday, June ...
(Date:5/26/2017)... , May 26, 2017  Endo International plc (NASDAQ: ... President and CEO, will represent the Company in a fireside ... Conference on Tuesday, June 13, 2017 at 10:40 a.m. PT ... Terranea Resort in Rancho Palos Verdes, CA. ... the event will be available on the Company,s website at ...
(Date:5/24/2017)... , May 24, 2017  ivWatch LLC ... Equipment Manufacturer (OEM) Board to enable seamless integration ... patient monitoring systems, infusion pumps and other devices. ... will be able to help health care customers ... reduced risks related to IV therapy. ...
Breaking Medicine Technology:
(Date:6/22/2017)... ... June 22, 2017 , ... United Benefit ... welcome Whipple & Company as its newest Partner Firm. Headquartered in Coconut Creek, ... clients’ risk while tailoring optimized benefit packages that strengthen the relationship between employer ...
(Date:6/22/2017)... ... June 22, 2017 , ... Children’s National ... Heart Association (AHA) to launch a Rheumatic Heart Disease Center, with the goal ... of rheumatic heart disease (RHD) in high-risk, financially disadvantaged countries and low-income communities ...
(Date:6/22/2017)... ... June 22, 2017 , ... ... environmental excellence. Maryland Recycling Network has awarded the Baltimore VA Medical Center, a ... Government Program Award for its efforts to promote waste reduction and promote recycling. ...
(Date:6/22/2017)... ... ... A June 12 article in The Star offers the advice ... oral hygiene by an aged parent who had recently suffered a series of minor ... steps, including scheduling a dentist visit. Northridge Dental Works, a Los Angeles Area dental ...
(Date:6/20/2017)... Murfreesboro, Tennessee (PRWEB) , ... June 20, 2017 ... ... chronic care services, announced today that Claritas Capital, a Nashville-based private equity firm, ... to accelerate our expansion plans for some time, and Claritas Capital offers the ...
Breaking Medicine News(10 mins):